Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

First phase II clinical trial of ABX-IL-8 begins in psoriasis

April 5, 2000

Draxis seeks approval of Levulan PDT in Canada

March 31, 2000

Organogenesis receives milestone payment related to Apligraf progress

March 30, 2000

TRK-820 demonstrates kappa-receptor-mediated antipruritic effects in animal model

March 29, 2000

SkyePharma and Bioglan establish marketing agreement for Solarase

March 23, 2000

FDA approves modifications to Dermagraft IDE for diabetic foot ulcers

March 23, 2000

Pharmadigm reports phase II results for DHEAS in burn patients

March 22, 2000

Chrysalin accelerates fracture healing in preclinical animal studies

March 22, 2000

Phase I trial results presented for IDEC-114 antibody in psoriasis

March 21, 2000

AstraZeneca pipeline includes novel chemokine receptor modulators

March 20, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.